| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -6,689 | -2,729 | -3,496 | -15,240 |
| Depreciation | NaN | NaN | NaN | 104 |
| Stock-based compensation expense | 2,278 | 2,607 | 2,628 | 5,854 |
| Depreciation | 60 | 80 | 58 | 100 |
| Amortization of debt discount and issuance costs | 68 | 63 | 70 | 104 |
| Non-cash interest expense | 77 | 75 | 73 | 390 |
| Pik interest incurred but not paid on term loan | NaN | 0 | 0 | 0 |
| Loss on debt extinguishment | NaN | 0 | 0 | -527 |
| Amortization of right-of-use asset | 453 | 442 | 433 | 835 |
| Unrealized loss on short-term investments | -165 | 0 | 82 | -41 |
| Inventory write-downs | 76 | 19 | 47 | 93 |
| Loss on disposal of property and equipment | 0 | -12 | 0 | -2 |
| Accounts receivable | 108 | -257 | 1,383 | 704 |
| Inventory | -125 | -1,221 | 1,836 | 3,058 |
| Prepaid expenses and other assets | 77 | -809 | 537 | -671 |
| Accounts payable | 2,195 | -2,385 | -48 | 1,703 |
| Accrued liabilities | -3,995 | 1,022 | 2,650 | -120 |
| Deferred revenue | -15 | -507 | -48 | 141 |
| Operating lease liabilities | -513 | -480 | -469 | -911 |
| Net cash used in operating activities | -5,900 | 506 | -1,944 | -9,568 |
| Proceeds from sale of short-term investments | NaN | 0 | 0 | 0 |
| Acquisition of property and equipment | 117 | 97 | 30 | 205 |
| Net cash used in investing activities | -117 | -97 | -30 | -205 |
| Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts and commissions-Follow On Offering | 0 | 0 | -50 | 69,704 |
| Proceeds from issuance of stock-At The Market Equity Offering | NaN | NaN | 0 | 232 |
| Proceeds from debt, net of discounts and issuance costs-At The Market Equity Offering | NaN | 0 | -133 | 58,568 |
| Repayment of debt-At The Market Equity Offering | NaN | 0 | 0 | 60,507 |
| Repurchase of common stock from kck ltd | 0 | 0 | 0 | 49,546 |
| Proceeds from issuance of common stock under employee plans | 10 | 723 | 1 | 1,151 |
| Taxes withheld and paid related to net share settlement of equity awards | 176 | 88 | 53 | 402 |
| Proceeds from at-the-market offering, net of sales commission-At The Market Equity Offering | 0 | 232 | NaN | NaN |
| Net cash (used in) provided by financing activities | -166 | 635 | -235 | 19,200 |
| Net increase (decrease) in cash and cash equivalents | -6,183 | 1,044 | -2,209 | 9,427 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 21,814 | 20,770 | 13,552 | NaN |
| Cash, cash equivalents and restricted cash at the end of the period | 15,631 | 21,814 | 20,770 | NaN |
NeuroPace Inc (NPCE)
NeuroPace Inc (NPCE)